Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.2 USD | +0.49% |
|
-34.71% | 0.00% |
22/04 | Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target | MT |
22/04 | Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target | MT |
- Stock Market
- Equities
- BOLD Stock
- News Boundless Bio, Inc.
- MarketScreener Strategies